Virchow Medical Strengthens Scientific Advisory Board with New Appointments

Key Takeaways

• Mayo Clinic Laboratories CEO Dr. William Morice joins Virchow’s Scientific Advisory Board
• Clinical Lab 2.0 founder Khosrow Shotorbani transitions to Virchow’s Scientific Advisory Board
• Four‑hour in‑person SAB meeting in San Diego set new product development priorities
• Board guidance aims to expand access to genomic testing for cancer patients
• Virchow’s Crow’s Nest system captures discarded biopsy material for biorepository storage

Pulse Analysis

The oncology diagnostics market faces a growing bottleneck: traditional formalin‑fixed paraffin‑embedded (FFPE) tissue often runs short, limiting the breadth of genomic sequencing that can guide targeted therapies. Virchow Medical’s Crow’s Nest Biopsy Catchment system tackles this gap by preserving high‑quality material from core‑needle biopsies that would otherwise be discarded. Stored in the CAP‑accredited Virchow Vault, these companion specimens enable oncologists to order sequencing on demand, expanding the pool of patients eligible for precision‑medicine trials and treatments.

The recent addition of Dr. William Morice, the CEO of Mayo Clinic Laboratories, and Khosrow Shotorbani, the founder of Clinical Lab 2.0, to Virchow’s Scientific Advisory Board injects deep expertise in laboratory medicine, value‑based testing, and data‑driven diagnostics. Morice’s academic and operational background at one of the nation’s leading clinical labs, combined with Shotorbani’s experience scaling reference‑lab operations, positions the advisory board to refine Virchow’s product roadmap, prioritize clinically meaningful innovations, and navigate regulatory pathways more efficiently. Their endorsement also signals to investors and hospital systems that Virchow’s technology aligns with emerging standards for specimen stewardship.

Looking ahead, the in‑person advisory meeting in San Diego set a clear agenda: accelerate the rollout of the Crow’s Nest system, expand the Virchow Vault’s network of hospital subscribers, and integrate real‑world data to demonstrate outcome improvements. As precision oncology gains traction and payers demand cost‑effective testing solutions, Virchow’s model could capture a sizable share of the $10 billion US molecular diagnostics market. Continued guidance from high‑profile advisors may also unlock strategic partnerships, positioning the company as a pivotal player in the next wave of cancer care innovation.